We were delighted to catch up with Professor Stefan Schreiber (University Hospital Schleswig-Holstein, Kiel, Germany) to discuss the results from the phase 3 ADVANCE and MOTIVATE studies, investigating risankizumab as an induction therapy in patients with moderate-to-severe Crohn’s Disease.
The abstract ‘Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies‘ (OP26) was presented at the 16th Congress of ECCO, July 2-3 & 8-10, 2021, Virtual.
Questions
- What is the rationale for the use of risankizumab as an induction therapy in patients with moderate-to-severe Crohn’s Disease (CD)? (0:15)
- Could you give us a brief overview of the ADVANCE and MOTIVATE studies, and what were the efficacy, safety and tolerability findings? (2:22)
Disclosures: Stefan Schreiber reports personal fees from Abbvie, Arena, BMS, Biogen, Celltrion, Celgene, IMAB, Gilead, MSD, Mylan, Pfizer, Fresenius, Janssen, Takeda, Theravance, provention Bio, Protagonist, Galapagos and Falk.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ECCO 2021 (Virtual).
